Aquestive Therapeutics Gestion
Gestion contrôle des critères 3/4
Nous ne disposons actuellement pas d’informations suffisantes sur le PDG.
Informations clés
Dan Barber
Directeur général
US$3.5m
Rémunération totale
| Pourcentage du salaire du PDG | 18.89% |
| Durée du mandat du directeur général | 4yrs |
| Propriété du PDG | 0.5% |
| Durée moyenne d'occupation des postes de direction | 3.2yrs |
| Durée moyenne du mandat des membres du conseil d'administration | 3.7yrs |
Mises à jour récentes de la gestion
Recent updates
Mise à jour du récit • May 25
AQST: 2026 NDA Resubmission Will Drive Allergy Treatment Upside Potential
Analysts have kept their fair value estimate for Aquestive Therapeutics steady at $11.00 while lowering near term growth and margin assumptions. Alongside a recent cut in one firm’s price target to $9.00 that breaks out Anaphylm, Libervant, other assets and net cash, they are focusing more on product specific drivers and regulatory timing than on broad multiple expansion.
Mise à jour du récit • May 02
AQST: FDA CRL Resolution And 2026 Resubmission Will Drive Long Term Upside
Analysts have trimmed their average price targets for Aquestive Therapeutics, with recent cuts such as Alliance Global's move to $9 from $12. These changes reflect updated views on Anaphylm's regulatory path and on the value of the broader pipeline and cash position.Mise à jour du récit • Apr 17
AQST: FDA Anaphylaxis Film Resubmission Timeline Will Shape Long Term Upside
Analysts have reduced their price targets for Aquestive Therapeutics to $9 per share, reflecting updated views on the timing and value contribution of Anaphylm, Libervant, and the company’s manufacturing and licensing assets following the recent FDA Complete Response Letter. Analyst Commentary Street research commentary around Aquestive Therapeutics has turned more cautious following the FDA Complete Response Letter for Anaphylm and the subsequent revision of expectations for the company’s product portfolio and assets.Mise à jour du récit • Apr 02
AQST: Regulatory Delay And 2026 Resubmission Will Ultimately Catalyze Allergy Treatment Upside
Analysts trimmed their price targets on Aquestive Therapeutics to around $9 per share. This reflects a reassessment of timing and risk after the FDA's Complete Response Letter on Anaphylm, even as they continue to ascribe value to Anaphylm, Libervant, existing manufacturing and royalty streams, and net cash.Mise à jour du récit • Mar 19
AQST: Regulatory Setbacks Will Ultimately Catalyze Future Allergy Treatment Upside
Aquestive Therapeutics' fair value estimate has been revised to $11.00 from $12.00 as analysts factor in updated assumptions around Anaphylm's regulatory timing and asset-level contributions following recent price target cuts and detailed sum of the parts analysis. Analyst Commentary Bullish analysts are reframing Aquestive Therapeutics primarily around the potential of Anaphylm, with updated fair value work that parses the business into distinct asset contributions.Seeking Alpha • Mar 11
Aquestive Therapeutics: With Some Hiccups, Anaphylm Is Closer To FDA Approval
Summary Aquestive Therapeutics remains a Buy, with an $8 fair value estimate and 87% upside, driven by Anaphylm’s FDA approval prospects. Anaphylm’s CRL issues are addressable, focused on packaging and labeling, not efficacy or safety, with a pivotal PK study planned for Q2–Q3 2026. I model 95% US and ~80% international adoption probability for Anaphylm and profitability by 2029, although they will likely need more financing by the end of 2027. Position sizing remains conservative at ~0.25x due to AQST’s one-product risk; I trim or close above fair value, monitoring FDA, partnerships, and financing needs. Read the full article on Seeking AlphaMise à jour du récit • Mar 05
AQST: FDA Feedback Will Delay Allergy Film Yet Preserve Long Term Upside
Narrative Update The Street has trimmed its average price target on Aquestive Therapeutics by $2, as analysts factor in the recent complete response letter on Anaphylm as a delay. They still view this delay as coming with a clearly defined, fixable path to a future approval decision.Mise à jour du récit • Feb 19
AQST: Regulatory Clarity On Allergy Treatment Will Drive Future Upside Potential
Aquestive Therapeutics' analyst price target has shifted from $14.49 to $12.00 as analysts factor in the recent complete response letter for Anaphylm, a modestly higher discount rate, and recalibrated assumptions for revenue growth, profit margin, and a higher future P/E multiple reflecting updated views on the regulatory path and risk profile. Analyst Commentary Bullish analysts acknowledge the complete response letter for Anaphylm as a key setback, but several see it as a definable regulatory event rather than a permanent roadblock.Article d’analyse • Feb 05
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares May Have Slumped 36% But Getting In Cheap Is Still Unlikely
Aquestive Therapeutics, Inc. ( NASDAQ:AQST ) shareholders that were waiting for something to happen have been dealt a...Mise à jour du récit • Feb 05
AQST: FDA Letters Create Delay Yet Future Allergy Franchise Upside Remains
Analysts have revised their fair value estimate for Aquestive Therapeutics from US$7.00 to US$6.00, citing reduced revenue growth assumptions and a slightly lower future P/E multiple following recent FDA communications and updated Street research on Anaphylm. Analyst Commentary Recent Street research around Anaphylm and the FDA feedback has led several bearish analysts to revisit their models and risk assumptions for Aquestive Therapeutics.Article d’analyse • Feb 04
Need To Know: The Consensus Just Cut Its Aquestive Therapeutics, Inc. (NASDAQ:AQST) Estimates For 2026
One thing we could say about the analysts on Aquestive Therapeutics, Inc. ( NASDAQ:AQST ) - they aren't optimistic...Mise à jour du récit • Jan 21
AQST: FDA Review Setback Will Still Support Long Term Allergy Franchise Upside
Narrative Update Analysts have trimmed their fair value estimate for Aquestive Therapeutics to US$7.00, citing the recent FDA deficiency letter on Anaphylm and a higher chance of a complete response letter that could delay potential market entry. Analyst Commentary Recent commentary from bearish analysts has focused on the regulatory setback for Anaphylm and its potential impact on Aquestive Therapeutics' valuation and execution risk.Mise à jour du récit • Jan 07
AQST: New Patents Will Extend Allergy Franchise Exclusivity And Support Future Upside
Analysts have lifted their price target on Aquestive Therapeutics to $12 from $9, citing new Anaphylm patents that extend brand exclusivity through at least 2037 and are viewed as meaningfully value accretive to the franchise. Analyst Commentary Recent research has centered on the new Anaphylm patents and what they might mean for Aquestive Therapeutics’ long term value.Mise à jour du récit • Dec 21
AQST: New Patents Will Extend Key Allergy Franchise Exclusivity Through 2037
Analysts have raised their price target on Aquestive Therapeutics to $12 from $9, reflecting a higher fair value estimate of about $8 per share as they factor in stronger projected revenue growth, modestly higher risk assumptions, and the value of new patents extending Anaphylm exclusivity through at least 2037. Analyst Commentary While the latest price target increase reflects growing confidence in Aquestive Therapeutics' long term prospects, it also raises the bar for execution.
Mise à jour du récit • Dec 07
AQST: Extended Patent Protection Will Support Future Share Price Outperformance
Analysts nudged their price targets on Aquestive Therapeutics higher by roughly $3 to $12, citing newly issued patents that extend Anaphylm's exclusivity through at least 2037 and growing confidence in FDA approval prospects following the decision not to convene an advisory committee for the NDA. Analyst Commentary Street research has turned increasingly constructive on Aquestive Therapeutics as recent developments around Anaphylm have prompted upward revisions to valuation models and a reassessment of execution risk.Mise à jour du récit • Nov 23
AQST: Multiple Patent Wins And Regulatory Progress Will Support Continued Share Price Outperformance
Analysts have raised their fair value estimate for Aquestive Therapeutics from $9.08 to $10.30. This change reflects recent patent wins for Anaphylm and improved regulatory outlooks, which are expected to enhance long-term growth and exclusivity for the company.Article d’analyse • Nov 15
Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Stock Retreats 27% But Revenues Haven't Escaped The Attention Of Investors
Aquestive Therapeutics, Inc. ( NASDAQ:AQST ) shares have retraced a considerable 27% in the last month, reversing a...Mise à jour du récit • Nov 07
AQST: Extended Patent Protection Will Drive Sustained Share Price Upside
Analysts have recently raised their price targets for Aquestive Therapeutics, with notable increases from $7 to $8 and from $9 to $12. They cite strengthened patent protection for Anaphylm and a smoother regulatory pathway as key drivers behind their more optimistic outlook.Mise à jour du récit • Oct 24
Patent Extensions and FDA Momentum Will Support Upcoming Needle-Free Epinephrine Launch
Analysts have recently raised their price targets for Aquestive Therapeutics, with increases up to $12 per share. They cite extended patent protection for Anaphylm and positive regulatory developments as key factors supporting a more optimistic outlook.Mise à jour du récit • Oct 09
Upcoming FDA Approval Will Enable Needle-Free Epinephrine Adoption
The analyst fair value estimate for Aquestive Therapeutics has been increased by $0.50 to $9.08. Analysts cite recent patent extensions and regulatory progress for Anaphylm as key drivers of the upward revision.Article d’analyse • Sep 05
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Stocks Shoot Up 28% But Its P/S Still Looks Reasonable
Aquestive Therapeutics, Inc. ( NASDAQ:AQST ) shares have continued their recent momentum with a 28% gain in the last...Article d’analyse • Aug 14
Earnings Update: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Just Reported And Analysts Are Trimming Their Forecasts
NasdaqGM:AQST 1 Year Share Price vs Fair Value Explore Aquestive Therapeutics's Fair Values from the Community and...Article d’analyse • Jul 21
After Leaping 29% Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Are Not Flying Under The Radar
Aquestive Therapeutics, Inc. ( NASDAQ:AQST ) shares have continued their recent momentum with a 29% gain in the last...Article d’analyse • May 16
Analysts Have Lowered Expectations For Aquestive Therapeutics, Inc. (NASDAQ:AQST) After Its Latest Results
The analysts might have been a bit too bullish on Aquestive Therapeutics, Inc. ( NASDAQ:AQST ), given that the company...
Nouveau récit • Mar 31
FDA Approval And Anaphylm Launch Will Expand Global Reach
Success in FDA approval for Anaphylm and Libervant expansion could significantly boost revenue and market penetration.Article d’analyse • Mar 21
Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) P/S Is On The Mark
When close to half the companies in the Pharmaceuticals industry in the United States have price-to-sales ratios (or...Seeking Alpha • Jan 06
Aquestive Therapeutics: Five Foci For 2025
Summary Aquestive Therapeutics' Anaphylm is nearing FDA approval, potentially disrupting the U.S. anaphylaxis market dominated by EpiPen, with peak sales estimated at $300–400M. AQST-108, a topical epinephrine gel for alopecia areata, shows promise with minimal side effects and could expedite its regulatory path, targeting a billion-dollar market. Libervant, a diazepam buccal film for cluster seizures, has gained orphan drug exclusivity, extending market exclusivity to 2031, ensuring a reliable revenue stream. Investors should monitor Aquestive's cash burn, partnerships, and earnings closely, as positive outcomes could significantly boost revenue, despite potential regulatory and commercial risks. I discuss my game plan for restarting my accumulation of AQST. Read the full article on Seeking AlphaArticle d’analyse • Dec 19
The Price Is Right For Aquestive Therapeutics, Inc. (NASDAQ:AQST) Even After Diving 25%
Unfortunately for some shareholders, the Aquestive Therapeutics, Inc. ( NASDAQ:AQST ) share price has dived 25% in the...Seeking Alpha • Nov 05
Aquestive: Rare Opportunity With Dual Platform Strategy
Summary Aquestive Therapeutics specializes in innovative film-based medicines and epinephrine products & delivery. The company's PharmFilm and Adrenaverse platforms offer unique competitive advantages, making it a strong investment opportunity. A risk-adjusted valuation indicates that Aquestive is currently undervalued compared to its market price. Understanding the fundamentals of competitive strategy highlights how Aquestive's platforms create sustainable economic moats. Read the full article on Seeking AlphaArticle d’analyse • Sep 07
Market Participants Recognise Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Revenues Pushing Shares 27% Higher
Aquestive Therapeutics, Inc. ( NASDAQ:AQST ) shares have continued their recent momentum with a 27% gain in the last...Seeking Alpha • Aug 20
Aquestive Therapeutics: Robust Development Of Oral Emergency Therapies Will Likely Pay Off Into 2025
Summary Aquestive Therapeutics shares surged 137.29% (YoY) after FDA approval of rival company ARS Pharmaceutical's "epinephrine nasal spray" Neffy. Market optimism surrounds AQST’s robust R&D pipeline, with analysts giving outperform rating and price target increase to $15. AQST recorded significant revenue growth in Q2 2024, with a cash balance of $89.87 million and sufficient funds until the end of 2026. Read the full article on Seeking AlphaArticle d’analyse • Aug 11
Rainbows and Unicorns: Aquestive Therapeutics, Inc. (NASDAQ:AQST) Analysts Just Became A Lot More Optimistic
Celebrations may be in order for Aquestive Therapeutics, Inc. ( NASDAQ:AQST ) shareholders, with the analysts...Article d’analyse • Jul 24
What Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) 30% Share Price Gain Is Not Telling You
Aquestive Therapeutics, Inc. ( NASDAQ:AQST ) shareholders are no doubt pleased to see that the share price has bounced...Article d’analyse • May 22
Aquestive Therapeutics, Inc. (NASDAQ:AQST) Shares Slammed 27% But Getting In Cheap Might Be Difficult Regardless
Aquestive Therapeutics, Inc. ( NASDAQ:AQST ) shares have retraced a considerable 27% in the last month, reversing a...Seeking Alpha • Apr 09
Aquestive Therapeutics: Positive Phase III Data Unlocks Additional Catalysts For 2024
Summary Aquestive Therapeutics has achieved positive Phase III data for their Anaphylm epinephrine sublingual film, showing comparable efficacy to auto-injectors. The company is moving forward with plans to file a New Drug Application (NDA) and has several upcoming catalysts, including self-administration and allergen studies. Anaphylm has the potential to disrupt the market dominated by auto-injectors, with global peak sales projected to surpass $1 billion. Read the full article on Seeking AlphaArticle d’analyse • Feb 28
Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Shares Climb 30% But Its Business Is Yet to Catch Up
Aquestive Therapeutics, Inc. ( NASDAQ:AQST ) shares have continued their recent momentum with a 30% gain in the last...Seeking Alpha • Jan 19
Aquestive Therapeutics: Anaphylm's Top-Line Data Could Reveal A Game-Changer In Q1
Summary Aquestive Therapeutics is nearing a key topline readout for its Anaphylm sublingual film, a potential groundbreaking oral epinephrine treatment for severe allergic reactions. If the data is positive, Anaphylm could be heading for a possible New Drug Application in 2024, with a potential commercial launch in 2025. Aquestive faces risks from regulatory hurdles, competition from other epinephrine treatments, and potential financial setbacks. Read the full article on Seeking AlphaArticle d’analyse • Jan 05
Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) Popularity With Investors Is Under Threat From Overpricing
With a median price-to-sales (or "P/S") ratio of close to 3.3x in the Pharmaceuticals industry in the United States...Analyse de la rémunération des PDG
| Date | Rémunération totale | Salaire | Bénéfices de l'entreprise |
|---|---|---|---|
| Mar 31 2026 | n/a | n/a | -US$69m |
| Dec 31 2025 | US$3m | US$660k | -US$84m |
| Sep 30 2025 | n/a | n/a | -US$69m |
| Jun 30 2025 | n/a | n/a | -US$65m |
| Mar 31 2025 | n/a | n/a | -US$54m |
| Dec 31 2024 | US$4m | US$633k | -US$44m |
| Sep 30 2024 | n/a | n/a | -US$35m |
| Jun 30 2024 | n/a | n/a | -US$26m |
| Mar 31 2024 | n/a | n/a | -US$29m |
| Dec 31 2023 | US$2m | US$600k | -US$8m |
| Sep 30 2023 | n/a | n/a | -US$12m |
| Jun 30 2023 | n/a | n/a | -US$23m |
| Mar 31 2023 | n/a | n/a | -US$33m |
| Dec 31 2022 | US$1m | US$542k | -US$54m |
| Sep 30 2022 | n/a | n/a | -US$71m |
| Jun 30 2022 | n/a | n/a | -US$73m |
| Mar 31 2022 | n/a | n/a | -US$69m |
| Dec 31 2021 | US$1m | US$424k | -US$71m |
| Sep 30 2021 | n/a | n/a | -US$62m |
| Jun 30 2021 | n/a | n/a | -US$64m |
| Mar 31 2021 | n/a | n/a | -US$54m |
| Dec 31 2020 | US$840k | US$410k | -US$56m |
| Sep 30 2020 | n/a | n/a | -US$48m |
| Jun 30 2020 | n/a | n/a | -US$50m |
| Mar 31 2020 | n/a | n/a | -US$68m |
| Dec 31 2019 | US$1m | US$389k | -US$66m |
Rémunération vs marché: La rémunération totale de Dan ($USD 3.49M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 2.64M ).
Rémunération et revenus: La rémunération de Dan a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.
PDG
Dan Barber (49 yo)
4yrs
Titularisation
US$3,493,559
Compensation
Mr. Daniel Barber, also known as Dan, is the Chief Executive Officer, President and Director at Aquestive Therapeutics, Inc. since May 17, 2022 and served as its Senior Vice President since April 2014 unti...
Équipe de direction
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO, President & Director | 4yrs | US$3.49m | 0.53% $ 2.7m | |
| Senior VP & CFO | 5.4yrs | US$1.32m | 0.23% $ 1.2m | |
| Corporate Secretary | 7.7yrs | US$1.35m | 0.18% $ 951.9k | |
| Chief Operating Officer | 3.5yrs | pas de données | 0.16% $ 841.5k | |
| Chief Legal Officer & Chief Compliance Officer | less than a year | pas de données | 0.080% $ 412.0k | |
| Senior Vice President of Information Technology & Chief People Officer | 3.2yrs | pas de données | 0.22% $ 1.2m | |
| Chief Medical Officer | less than a year | pas de données | 0.061% $ 317.2k | |
| Chief Commercial Officer | less than a year | pas de données | 0.19% $ 993.4k | |
| Senior Vice President of Regulatory Affairs | no data | pas de données | 0.10% $ 531.1k | |
| Chief Development Officer | less than a year | pas de données | 0.080% $ 412.0k | |
| VP of Finance | no data | pas de données | pas de données |
3.2yrs
Durée moyenne de l'emploi
54yo
Âge moyen
Gestion expérimentée: L'équipe de direction de AQST est considérée comme expérimentée (ancienneté moyenne 3.2 ans).
Membres du conseil d'administration
| Nom | Position | Titularisation | Compensation | Propriété |
|---|---|---|---|---|
| CEO, President & Director | 4yrs | US$3.49m | 0.53% $ 2.7m | |
| Independent Director | 3.8yrs | US$237.61k | 0% $ 0 | |
| Independent Chairman of the Board | 19.2yrs | US$274.64k | 0.060% $ 309.3k | |
| Independent Director | 5.3yrs | US$233.22k | pas de données | |
| Independent Vice Chairman of the Board | 22.3yrs | US$240.92k | 0.079% $ 409.9k | |
| Independent Director | 5.3yrs | US$213.41k | 0% $ 0 | |
| Member of Scientific Advisory Board | 3.7yrs | pas de données | pas de données | |
| Member of Scientific Advisory Board | 3.7yrs | pas de données | pas de données | |
| Member of Scientific Advisory Board | 3.7yrs | pas de données | pas de données | |
| Member of Scientific Advisory Board | 3.7yrs | pas de données | pas de données | |
| Member of Scientific Advisory Board | 3.7yrs | pas de données | pas de données | |
| Member of Scientific Advisory Board | 3.7yrs | pas de données | pas de données |
3.7yrs
Durée moyenne de l'emploi
64yo
Âge moyen
Conseil d'administration expérimenté: Les membres du conseil d'administration de AQST sont considérés comme expérimentés (ancienneté moyenne 3.7 ans).
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/26 20:23 |
| Cours de l'action en fin de journée | 2026/05/22 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Aquestive Therapeutics, Inc. est couverte par 13 analystes. 9 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| James Molloy | Alliance Global Partners |
| Gary Nachman | BMO Capital Markets Equity Research |
| Kristen Kluska | Cantor Fitzgerald & Co. |